Serina Therapeutics Inc (SER)

Serina Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-0.89	5.27	-2.68	-8.68	-10.87	-12.15
Depreciation & Amortization	0.3	0.26	0.21	0.13	1.26	0.95
Share-Based Compensation	0.01	0.02	0.01	1	0.91	1.91
Other Operating Activities	-1.61	-8.03	0.39	-0.31	0.88	-0.86
Operating Cash Flow	-2.19	-2.48	-2.08	-7.86	-7.82	-10.16
Capital Expenditures	-0.52	-0.5	-0.01	0	-0.02	-0.64
Acquisitions	10	0	0	0.42	0	0
Change in Investments	0	0	0.99	0.25	0	0.35
Other Investing Activities	-	-	-	-	-	-0.07
Investing Cash Flow	9.48	-0.5	0.98	0.67	-0.02	-0.36
Share Issuance / Repurchase	0.02	0.01	0	0.5	0	4.5
Debt Issued / Paid	0.94	10.05	1.31	6.75	6.12	1.77
Other Financing Activities	0.34	-	-	-	-0.16	-
Financing Cash Flow	1.3	10.07	1.31	7.25	5.96	6.27
Exchange Rate Effect	0	0	0	0	0	0
Net Cash Flow	8.59	7.09	0.22	0.06	-1.88	-4.26
Free Cash Flow	-2.71	-2.98	-2.09	-7.86	-7.84	-10.8
Free Cash Flow Margin	-85.98%	-94.53%	-352.55%	-5454.86%	-2170.91%	-625.06%
Free Cash Flow Per Share	-0.97	-1.30	-0.97	-7.29	-7.32	-10.19

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).